Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland

Last updated: April 29, 2025
Sponsor: Swiss Society of Dermatology and Venereology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Allergy

Rash

Dermatitis, Atopic

Treatment

N/A

Clinical Study ID

NCT05819463
2022-00205
  • Ages > 12
  • All Genders

Study Summary

As structured and detailed data on the management of AD, a common chronic inflammatory skin disease which has a high impact on patients' quality of life and socioeconomic burden, are not available in Switzerland, the planned registry will overcome this gap. It will provide data on the medical care of patients with AD for health care research and allow to study the efficacy and safety of approved and available therapies for AD in daily life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 12 years

  • AD according to the UK Working Party's Diagnostic Criteria (28)

  • Moderate to severe AD as defined by

  • objective SCORAD > 20 or IGA ≥ 3 (moderate) or

  • currently on systemic antiinflammatory therapy for AD or

  • previous systemic antiinflammatory therapy for AD within past 24 months

Exclusion

Exclusion Criteria:

  • refusal to sign the informed consent form

Study Design

Total Participants: 700
Study Start date:
June 02, 2022
Estimated Completion Date:
December 31, 2032

Study Description

A prospective, non-interventional, national multicenter study in patients with moderate-to-severe AD. According to the availability of approved systemic drugs for the treatment of AD, the study will include children ≥12 years, adolescents and adult patients.

The general goal of the AD registry TREATswitzerland is to provide the scientific community with a disease-oriented prospective cohort of patients suffering from moderate-to-severe AD.

The primary objective of the AD registry is the documentation of medical care given to patients with moderate-to-severe AD in order to assess the appropriateness of care.

Further objectives of the AD registry are:

  1. to evaluate the psychosocial impact of AD;

  2. to provide up-to-date epidemiologic data that allow investigating risk factors for favorable or unfavorable disease courses and comorbidities; and

  3. to establish a research network and foster clinical research projects.

The study procedures include:

  • No study related intervention will be performed

  • Patients have to fulfill all inclusion criteria to be enrolled in the study.

  • Included patients are prospectively followed for at least 24 months. A maximum duration of follow-up is not intended.

  • During the observation period, standardized study visits are performed to prospectively document patient characteristics, clinical data, patient-reported outcomes, reasons for treatment decisions, and satisfaction with treatment.

Connect with a study center

  • Universitätsspital Basel, Allergologie

    Basel, 4031
    Switzerland

    Active - Recruiting

  • Inselspital, Department of Dermatology

    Bern, 3010
    Switzerland

    Active - Recruiting

  • Dermatology & Skin Care Clinic

    Buochs, 6374
    Switzerland

    Active - Recruiting

  • HFR Hôpital Cantonal de Fribourg

    Fribourg, 1752
    Switzerland

    Active - Recruiting

  • Dermatologie CHUV

    Lausanne, 1011
    Switzerland

    Active - Recruiting

  • Luzerner Kantonsspital, Zentrum für Dermatologie und Allergologie

    Luzern, 6000
    Switzerland

    Site Not Available

  • Kantonsspital St. Gallen - Klinik für Dermatologie, Venerologie und Allergologie

    St. Gallen, 9007
    Switzerland

    Active - Recruiting

  • PLAZA Kliniken

    Uster, 8610
    Switzerland

    Active - Recruiting

  • Institut für Dermatologie und Venerologie Stadtspital Zürich Europaallee

    Zürich,
    Switzerland

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.